Skip to main content

Table 1 Patient characteristics

From: Early menopause and severity of rheumatoid arthritis in women older than 45 years

  All patients
n= 134
Mean age at diagnosis; years (SD) (range) 63.2 (8.3) (47-80)
Mean follow-up time; years (SD) 10.1 (3.5)
RF positive (%) 94/132 (71.2)
Anti-CCP positive (%) 34/57 (59.6)
Smoking at diagnosis (%) 39/118 (33.1)
Low formal education (< 8 years of school) (%) 66/128 (49.3)
Prednisolone at diagnosis (%) 39/120 (32.5)
Biological treatment ever (%) 37/133 (27.8)
Number of used DMARDS; median (IQR) 2 (1-3)
> 3 DMARDs used (%) 30 (22.4)
DMARDS in combination (%) 54 (40.3)
Documented radiographic erosions (ever) (%) 71/125 (56.8)
Severe extraarticular manifestations (%) 7 (5.2)
Median HAQ at diagnosisa 0.87
Median HAQ 1 year after diagnosisa 0.75
Median HAQ 5 years after diagnosisa 0.75
Median HAQ 10 years after diagnosisa 0.88
  1. CCP, cyclic citrullinated peptide; DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; IQR, interquartile range; RF, rheumatoid factor; SD, standard deviation. aData available for HAQ at diagnosis in 70 cases, for HAQ at 1 year in 82 cases, for HAQ at 5 years in 92 cases, and for HAQ at 10 years in 63 cases.